The British MS Society has launched a new campaign called #ApprovedButDenied as part of its fundraising efforts to provide palliative care for those living with multiple sclerosis. The scheme is designed specifically to allow people access to cannabis-based medicines that have been approved by the NHS but not yet made available on prescription without needing an official medical document from their doctor.

The “ms society uk” is a campaign that has been launched by the UK MS Society. The campaign will focus on the issue of cannabis being approved but not allowed to be prescribed by doctors.

The-UK-MS-Society-Launches-ApprovedButDenied-Cannabis-Campaign

 

 

The MS Society is speaking out against the absence of medicinal cannabis access in the United Kingdom.

Despite studies and personal reports of its efficacy as a medication for MS patients, according to a study published by the MS Society, not nearly enough medical cannabis patients have been able to receive medical cannabis via the National Health Service (NHS).

The MS Society is speaking out about the lack of development and access to cannabis in the United Kingdom, despite the fact that medicinal cannabis has been legal in the country for almost three years. The group has launched the #ApprovedButDenied campaign to raise awareness about the lack of appropriate access, as well as a 30-page study containing statistics on MS sufferers in the United Kingdom.

On its website, the group said that “Sativex, a cannabis-based spray, was authorized in England in 2019 for use in moderate to severe spasticity after other therapies have failed.” “Despite this, many individuals with MS are still unable to get Sativex because their local health authorities, known as Clinical Commissioning Groups (CCGs), refuse to prescribe medication. As a consequence, Sativex is only supported in 49 of 106 CCGs, which is an unacceptable postcode lottery. This must change; everyone with MS is entitled to adequate treatment.” 

According to the organization’s study, just 49 out of 106 CCGs endorse Sativex. Only 630 individuals had access to Sativex in May 2021, according to the National Institute for Health and Care Excellence (NICE). 4,800 people are now eligible for a four-week Sativex trial to determine whether the medication works for them (which is the most current data that was available at the time the report was written).

Fredi Cavander-Attwood, Policy Manager for the MS Society, voiced her dissatisfaction with the lack of progress for MS sufferers in England. “It is absolutely unacceptable that Sativex is only accessible in 49 out of 106 health districts in England two years after obtaining NICE approval,” Cavander-Attwood said. “MS is a persistent, painful, and debilitating disease, and receiving the therapy you need shouldn’t be a gamble.”

#ApprovedButDenied

The #ApprovedButDenied campaign also draws attention to the inequitable state of the “postcode lottery” that decides which MS patients are eligible for medicinal marijuana. Some individuals are forced to choose between living in agony and paying up to £500 per month for a Sativex prescription (which costs £300 on the NHS). Patients often turn to purchasing medication on the illicit market, according to Cavander-Attwood.

The MS Society also conducted interviews with a few MS sufferers, whose answers were included in the study. With Sativex, one patient, Neil, was able to get a good night’s sleep.

“I got my first decent night’s sleep in ten years after beginning on Sativex. I didn’t have MS fatigue, but until I got some sleep, I didn’t know how much I was running on fumes due to a lack of sleep. It wasn’t until it ended that I realized how difficult it was.”

Another patient, Sheila, had relief from her problems after using medicinal cannabis. “I can easily exercise my arms and legs after taking Sativex,” she added. “I haven’t seen any changes in my MS symptoms. I haven’t had any spasms in a long time. I can move my limbs without worry of unpleasant spasms after taking Sativex. I can accomplish more now that I’m not afraid about triggering spasms. And the spasms were causing me so much pain.”

The MS Society’s study contains a number of recommendations, including requests for CCGs/prescribers, the UK government, the NHS, and Sativex’s producer to all take constructive measures to improve MS sufferers’ present condition.

The group said, “Sativex is not a ‘miracle medication,’ since it does not work for everyone with spasticity.” “However, when it works, the results may be life-changing. People with MS, such as Neil and Sheila, who share their experiences in this article, say their spasms and associated agony have gone away, allowing them and their families to enjoy their lives rather than simply exist.”

The UK MS Society Launches #ApprovedButDenied Cannabis Campaign. The campaign is an attempt to raise awareness about the effects of cannabis on people with multiple sclerosis. Reference: ms society shop.

  • ms-uk
  • multiple sclerosis trust
  • multiple sclerosis charity
  • ms trust uk
  • what do the ms society do
You May Also Like

AZ NORML Offering Expungement Clinics at Phoenix Dispensary

While the state of Arizona has seen a decrease in the number…

North Bay Cities Take Differing Approaches to Cannabis Dispensaries

The future of cannabis is in the hands of cities. From San…

Best Practices for Commercial Cannabis Propagation

The Cannabis industry is experiencing rapid growth, but not all growers are…

After Connecticut legalizes marijuana, only 2 New England states now prohibit cannabis

The following is a compilation of statistics and other information gathered from…